Drugs / Trivalent Inactivated Influenza Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01008137 | Oct → Dec 2009 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Inactivated Influenza Vaccine | “Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the...” NCT01008137 ↗ |
| Known as | ANFLU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01008137 ↗ |
| Modality | Vaccine | “Trivalent Inactivated Influenza Vaccine (ANFLU)” NCT01008137 ↗ |
| Route | Intramuscular | “administered as a single 0.5 mL intramuscular injection” NCT01008137 ↗ |